REFERENCES
- Descamps-Lascha, B.; Herbelin, A.; Nguyen, A T.; Roux-Lombard, P.; Zingraff, J.; Moynot, A.; Verger, C.; Dahmane, D.; de Groote, D.; Jungers, P.; Dayer, J T. Balance between Il-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationship with activation markers of T cells, B cells, and monocytes.. J. Immunol. 1995, 15, 882–892.
- Descamps-Lascha, B.; Chatenoud, L. T cells and B cells in chronic renal failure. Semin. Nephrol. 1996, 16, 183–191. [CSA]
- Girndt, M.; Sester, M.; Sester, U.; Kaul, H.; Kohler, H. Molecular aspects of T- and B-cell function in uremia. Kidney Int. 2001, 78 (Suppl.), S206–211. [CSA]
- Altun, B.; Erdem, Y.; Usalan, C.; Haznedaroglu, I C.; Yasavul, U.; Turgan, C.; Caglar, S.; Kirazli, S. Determinants of soluble CD23 antigen levels inhemodialysis patients: 1,25 dihydroxyvitamin D3 and recombinant human erythropoietin treatment. Clin. Nephrol. 1999, 52, 230–238. [PUBMED], [INFOTRIEVE], [CSA]
- Stefanovic, V.; Antic, S.; Mitic-Zlatkovic, M.; Vlahovic, P. Reversal of increased lymphocyte PC-1 activity in patients with type 2 diabetes treated with metformin. Diabetes/Metab. Res. Rev. 1999, 15, 400–404. [CROSSREF], [CSA]
- Stefanovic, V.; Golubovic, E.; Vlahovic, P.; Mitic-Zlatkovic, M. Lymphocyte ectoenzymes in childhood idiopathic nephrotic syndrome. Pediatr. Nephrol. 1998, 12, 755–760. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Djordjevic, V.; Radivojević, J.; Stefanovic, V. Improvement of anemia in hemodialysis patients after pulse oral 1-α-D3 treatment. Clin. Nephrol. 2002, 57, 487–888. [PUBMED], [INFOTRIEVE], [CSA]
- Spaia, S.; Pangalos, M.; Askepidis, N.; Pazarloglou, M.; Mavropoulou, E.; Theodoridis, S. Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron 2000, 84, 320–325. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vlahovic, P.; Stefanovic, V. Kidney exopeptidases. Structure, functions and clinical significance. Path. Biol. 1998, 46, 779–786. [CSA]
- Descamps-Lascha, B.; Jungers, P.; Witko-Sarsat, V. Immune system dysregulation in uremia: role of oxidative stress. Blood Purif. 2002, 20, 481–484. [CROSSREF], [CSA]
- Chalmers, A H.Blake-Mortimer, J S.Winefield, A H. Lymphocyte 5′-ectonucleotidase: an indicator of oxidative stress in humans? Redox. Rep. 2000, 5, 89–91. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Danielski, M.; Ikizler, T A.McMonagle, E.; Kane, J C.Pupim, L.; Morrow, J.; Himmelfarb, J. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am. J. Kidney Dis. 2003, 42, 286–294. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Dasgupta, A.; Hussain, S.; Ahmad, S. Increased lipid peroxidation in patients on maintenance hemodialysis. Nephron 1992, 60, 56–59. [PUBMED], [INFOTRIEVE]
- Ward, R A.McLeish, K R. Oxidant stress in hemodialysis patients: what are the determining factors. Artif. Organs. 2003, 27, 230–236. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ward, R A.Ouseph, R.; McLeish, K R. Effects of high-flux hemodialysis on oxidant stress. Kidney Int. 2003, 63, 353–359. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Koken, T.; Serteser, M.; Kahraman, A.; Gokce, C.; Demir, S. Changes in serum markers of oxidative stress with varying periods of haemodialysis. Nephrology (Carlton) 2004, 9, 77–82. [CROSSREF], [CSA]
- Oka, Y.; Miyazaki, M.; Takatsu, S.; Kunitomo, K.; Kokumai, Y.; Matsuda, H.; Maruyama, M. Lowering of oxidative stress in hemodialysis patients by dialysate cleaning: in relation to arteriosclerosis. Ther. Apher. Dial. 2004, 8, 313–319. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Tepel, M.; van der Giet, M.; Statz, M.; Jankowski, J.; Zidek, W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003, 107, 992–995. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Usberti, M.; Gerardi, G.; Bufano, G.; Tira, P.; Micheli, A.; Albertini, A.; Floridi, A.; Di Lorenzo, D. Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients. Am. J. Kidney Dis. 2002, 40, 590–599. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kobayashi, S.; Moriya, H.; Aso, K.; Ohtake, T. Vitamin E-bonded hemodialyzer improves atherosclerosis associated with a rheological improvement of circulating red blood cells. Kidney Int. 2003, 63, 1881–1887. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Antolini, F.; Valente, F.; Ricciardi, D.; Fagugli, R M. Normalization of oxidative stress parameters after kidney transplant is secondary to full recovery of renal function. Clin. Nephrol. 2004, 62, 131–137. [PUBMED], [INFOTRIEVE]
- Mak, R H.K.Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia. Am. J. Physiol. 1996, 270, F839–F894. [PUBMED], [INFOTRIEVE]
- Celo, L A.Stanic, L.; Davis, P A.; Pagnin, E.; Munaretto, G.; Fusaro, M.; Landini, S.; Semplicini, A.; Picolli, A. Effect of epoetin on Ho-1 mRNA level and plasma antioxidants in hemodialysis patients. Int. J. Clin. Pharmacol. Ther. 2003, 41, 187–192.
- Borawski, J.; Mysliwiec, M. Effect of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients. Clin. Appl. Thromb. Hemost. 2002, 8, 77–84. [PUBMED], [INFOTRIEVE], [CSA]